(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 37.94% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Iovance Biotherapeutics's revenue in 2026 is $285,608,000.On average, 12 Wall Street analysts forecast IOVA's revenue for 2026 to be $164,772,779,196, with the lowest IOVA revenue forecast at $154,025,466,524, and the highest IOVA revenue forecast at $173,372,415,343. On average, 11 Wall Street analysts forecast IOVA's revenue for 2027 to be $229,600,462,071, with the lowest IOVA revenue forecast at $196,907,556,636, and the highest IOVA revenue forecast at $265,825,201,459.
In 2028, IOVA is forecast to generate $344,722,174,832 in revenue, with the lowest revenue forecast at $245,040,514,925 and the highest revenue forecast at $519,728,788,944.